Overcoming antibiotic-resistant Helicobacter pylori infection: Current challenges and emerging approaches DOI

Gabriel Reis Rocha,

Fabian Fellipe Bueno Lemos,

Luis Guilherme de Oliveira Silva

et al.

World Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: 31(10)

Published: Feb. 26, 2025

Recent studies have shown a noticeable increase in global Helicobacter pylori (H. ) resistance , with clarithromycin surpassing 15% various areas. However, inadequate epidemiological monitoring, especially developing countries, and the absence of uniform testing methods lead to discrepancies between regions possible underestimation levels. The complexity treating H. is driven by its highly dynamic genome, which prone frequent mutations contributing phenotypical resistance. usual course action empirical treatment involves using combination drugs simultaneously, leading significant selection pressure potential side effects. emergence strains resistant multiple closely tied failures first-line treatment, highlighting need prevent further optimal initial therapy or regimens guided antibiotic susceptibility testing, requiring collection mixed samples isolates for accurate assessment. new treatments like potassium-competitive acid blockers offers hopeful approach decrease antimicrobial usage while still ensuring effectiveness comparison traditional therapies proton pump inhibitors. Additionally, use probiotics under investigation identify specific formulations that may mitigate therapy-associated adverse

Language: Английский

Overcoming antibiotic-resistant Helicobacter pylori infection: Current challenges and emerging approaches DOI

Gabriel Reis Rocha,

Fabian Fellipe Bueno Lemos,

Luis Guilherme de Oliveira Silva

et al.

World Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: 31(10)

Published: Feb. 26, 2025

Recent studies have shown a noticeable increase in global Helicobacter pylori (H. ) resistance , with clarithromycin surpassing 15% various areas. However, inadequate epidemiological monitoring, especially developing countries, and the absence of uniform testing methods lead to discrepancies between regions possible underestimation levels. The complexity treating H. is driven by its highly dynamic genome, which prone frequent mutations contributing phenotypical resistance. usual course action empirical treatment involves using combination drugs simultaneously, leading significant selection pressure potential side effects. emergence strains resistant multiple closely tied failures first-line treatment, highlighting need prevent further optimal initial therapy or regimens guided antibiotic susceptibility testing, requiring collection mixed samples isolates for accurate assessment. new treatments like potassium-competitive acid blockers offers hopeful approach decrease antimicrobial usage while still ensuring effectiveness comparison traditional therapies proton pump inhibitors. Additionally, use probiotics under investigation identify specific formulations that may mitigate therapy-associated adverse

Language: Английский

Citations

0